Gas chromatographic negative ion mass spectrometric assay of 2-dicyclopropylmethylamino-2-oxazoline (S-3341), a new antihypertensive drug

Publisher Website
Google Scholar
Abstract
The quantification in plasma and urine of 2‐dicyclopropylmethylamino‐2‐oxazoline (S‐3341), a new antihypertensive drug is described using a sensitive gas chromatographic negative ion mass spectrometric method with ammonia as moderating gas. After a two‐step extraction, derivatization is carried out with 3,5‐bis(trifluoromethyl)benzoyl chloride and the abundance of the molecular ion (m/z 420) obtained is compared with that of the tetradeuterated standard (m/z 424). The low background due to the high mass and negative ion detection provides a detection limit of about 1 pg per injection. Oral administration of 1 or 2 mg S‐3341 to patients gives a maximum concentration of 3.3±0.7 ng ml−1 and 7.6±2.0 ng ml−1 at 1.8±0.6 h and 1.4±0.7 h and an average elimination half‐life of 6.7 h.

This publication has 2 references indexed in Scilit: